AMNEAL PHARMACEUTICALS INC CLASS A (AMRX) — insider trading
Health Care · NASDAQ
AMNEAL PHARMACEUTICALS INC CLASS A (AMRX) has 36 reported SEC Form 4 insider transactions in our data, including 1 open-market sale among the most recent 36 (latest 2026-05-11).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-05-11 | Autor Deborah M. | Director | Open-market sale | 34,819 | $12.94 | $450.6K | Form 4 |
| 2026-05-07 | Yanai Shlomo | Director | Option exercise / conversion (derivative) | 34,819 | $0.00 | $0 | Form 4 |
| 2026-05-07 | Yanai Shlomo | Director | Option exercise / conversion | 34,819 | — | — | Form 4 |
| 2026-05-07 | MEISTER PAUL M | Director | Option exercise / conversion (derivative) | 48,747 | $0.00 | $0 | Form 4 |
| 2026-05-07 | MEISTER PAUL M | Director | Option exercise / conversion | 48,747 | — | — | Form 4 |
| 2026-05-07 | Nark Ted C | Director | Option exercise / conversion (derivative) | 34,819 | $0.00 | $0 | Form 4 |
| 2026-05-07 | Nark Ted C | Director | Option exercise / conversion | 34,819 | — | — | Form 4 |
| 2026-05-07 | Kiely John | Director | Option exercise / conversion (derivative) | 34,819 | $0.00 | $0 | Form 4 |
| 2026-05-07 | Kiely John | Director | Option exercise / conversion | 34,819 | — | — | Form 4 |
| 2026-05-07 | Patel Gautam | Director | Option exercise / conversion (derivative) | 34,819 | $0.00 | $0 | Form 4 |
| 2026-05-07 | Patel Gautam | Director | Option exercise / conversion | 34,819 | — | — | Form 4 |
| 2026-05-07 | George Jeffrey P. | Director | Option exercise / conversion (derivative) | 34,819 | $0.00 | $0 | Form 4 |
| 2026-05-07 | George Jeffrey P. | Director | Option exercise / conversion | 34,819 | — | — | Form 4 |
| 2026-05-07 | Autor Deborah M. | Director | Option exercise / conversion (derivative) | 34,819 | $0.00 | $0 | Form 4 |
| 2026-05-07 | Autor Deborah M. | Director | Option exercise / conversion | 34,819 | — | — | Form 4 |
| 2026-05-07 | BUCHI J KEVIN | Director | Option exercise / conversion (derivative) | 34,819 | $0.00 | $0 | Form 4 |
| 2026-05-07 | BUCHI J KEVIN | Director | Option exercise / conversion | 34,819 | — | — | Form 4 |
| 2026-05-06 | Yanai Shlomo | Director | Grant / award / vesting (derivative) | 19,824 | $0.00 | $0 | Form 4 |
| 2026-05-06 | MEISTER PAUL M | Director | Grant / award / vesting (derivative) | 30,837 | $0.00 | $0 | Form 4 |
| 2026-05-06 | Nark Ted C | Director | Grant / award / vesting (derivative) | 19,824 | $0.00 | $0 | Form 4 |
| 2026-05-06 | Kiely John | Director | Grant / award / vesting (derivative) | 19,824 | $0.00 | $0 | Form 4 |
| 2026-05-06 | Patel Gautam | Director | Grant / award / vesting (derivative) | 19,824 | $0.00 | $0 | Form 4 |
| 2026-05-06 | George Jeffrey P. | Director | Grant / award / vesting (derivative) | 19,824 | $0.00 | $0 | Form 4 |
| 2026-05-06 | Autor Deborah M. | Director | Grant / award / vesting (derivative) | 19,824 | $0.00 | $0 | Form 4 |
| 2026-05-06 | BUCHI J KEVIN | Director | Grant / award / vesting (derivative) | 19,824 | $0.00 | $0 | Form 4 |
| 2026-03-04 | Patel Chintu | Director, Officer (Co-CEO) | Option exercise / conversion (derivative) | 92,593 | $0.00 | $0 | Form 4 |
| 2026-03-04 | Patel Chintu | Director, Officer (Co-CEO) | Shares withheld for taxes / exercise cost | 28,983 | $13.30 | $385.5K | Form 4 |
| 2026-03-04 | Patel Chintu | Director, Officer (Co-CEO) | Option exercise / conversion | 92,593 | — | — | Form 4 |
| 2026-03-03 | Patel Chintu | Director, Officer (Co-CEO) | Option exercise / conversion (derivative) | 733,944 | $0.00 | $0 | Form 4 |
| 2026-03-03 | Patel Chintu | Director, Officer (Co-CEO) | Option exercise / conversion (derivative) | 59,931 | $0.00 | $0 | Form 4 |
| 2026-03-03 | Patel Chintu | Director, Officer (Co-CEO) | Shares withheld for taxes / exercise cost | 315,885 | $13.31 | $4.20M | Form 4 |
| 2026-03-03 | Patel Chintu | Director, Officer (Co-CEO) | Option exercise / conversion | 733,944 | — | — | Form 4 |
| 2026-03-03 | Patel Chintu | Director, Officer (Co-CEO) | Shares withheld for taxes / exercise cost | 17,112 | $13.31 | $227.8K | Form 4 |
| 2026-03-03 | Patel Chintu | Director, Officer (Co-CEO) | Option exercise / conversion | 59,931 | — | — | Form 4 |
| 2026-03-02 | Patel Chirag K. | Director, Officer (President & Co-CEO) | Grant / award / vesting (derivative) | 544,663 | $0.00 | $0 | Form 4/A |
| 2026-03-02 | Patel Chintu | Director, Officer (Co-CEO) | Grant / award / vesting (derivative) | 544,663 | $0.00 | $0 | Form 4/A |
Ask the chat about AMRX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: AMNEAL PHARMACEUTICALS INC CLASS A (AMRX).
Last updated 2026-05-11 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.